32a200c7-6f8a-4393-ae39-48c73b7935cf
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.300
- HEDGEHOG_SIGNALING+0.300
- MYC_TARGETS_V1+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- G2M_CHECKPOINT+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- ANDROGEN_RESPONSE+0.100
- DNA_REPAIR+0.100
- MYC_TARGETS_V2+0.100
- NOTCH_SIGNALING+0.100
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- APICAL_SURFACE-0.400
- COMPLEMENT-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- INFLAMMATORY_RESPONSE-0.400
- APOPTOSIS-0.300
- COAGULATION-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0112225 | — | — | 0.879 |
| 2 | TCGA-56-7223-01A-11R-2045-07 | — | cohortMD1 | 0.878 |
| 3 | C3N-02283 | — | cohortMD1 | 0.874 |
| 4 | EPT0810 | EPN | Posterior Fossa EPN | 0.873 |
| 5 | MNG239 | — | — | 0.866 |
| 6 | e97f9781-5033-40bd-bc5c-7a703ef965b1 | — | — | 0.865 |
| 7 | BS_QWNBZ9RJ | Embryonal tumors | — | 0.860 |
| 8 | TCGA-E2-A15R-01A-11R-A115-07 | — | B | 0.858 |
| 9 | SRR2780123 | — | — | 0.857 |
| 10 | SRR8526717 | — | cohortMD1 | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |